Senores Pharmaceuticals Ltd is a global research-driven pharmaceutical company specializing in the development and manufacturing of pharmaceutical products. The company primarily caters to regulated markets, including the US, Canada, and the United Kingdom, across various therapeutic areas and dosage forms, while also maintaining a presence in emerging markets. It focuses on developing and manufacturing specialty, underpenetrated, and complex pharmaceutical products that adhere to international quality standards.
The company was originally incorporated as Senores Pharmaceuticals Private Limited on December 26, 2017, and subsequently converted into a Public Limited Company on September 4, 2023. Its product portfolio encompasses tablets, capsules, liquids, dry syrups, oral rehydration solutions, active pharmaceutical ingredients (APIs), and critical care injectables, including antibiotics, anti-bacterial, anti-fungal, and blood line products. Senores Pharmaceuticals also engages in product exports and provides consulting and licensing services.
Senores Pharmaceuticals currently holds a market capitalization of approximately ₹2,615-2,769 crores as of June 2025. The company's stock has experienced significant volatility, with a 52-week high of ₹664.00 and a 52-week low of ₹440.00. Promoter holding has remained stable at 45.77% as of March 2025.
The company has demonstrated a remarkable financial growth trajectory. For the full year ended March 2025, net profit surged by 86.20% to ₹58.56 crores, up from ₹31.45 crores in the previous year. Concurrently, sales increased by 85.65% to ₹398.25 crores from ₹214.52 crores. In Q4 FY25, the net profit saw an 11.86% increase to ₹17.83 crores, with sales growing by 11.49% to ₹114.21 crores compared to the corresponding quarter in the previous year.
• Q4 FY25 Performance: Net Profit of ₹17.83 crores, Sales of ₹114.21 crores
• FY25 Performance: Net Profit of ₹58.56 crores, Sales of ₹398.25 crores
• Trailing 12-Month Operating Revenue: ₹612.77 crores
• Annual Revenue Growth: 92%
• Pre-Tax Margin: 18%
• Return on Equity (ROE): 7%
• Market Capitalization: ₹2,615-2,769 crores (as of June 2025)
• Promoter Holding: 45.77% (as of March 2025)
• Debt to Equity Ratio: 21%
• Stock P/E Ratio: 47.5
• Book Value: ₹171
Senores Pharmaceuticals has been actively pursuing strategic acquisitions to expand its portfolio within the US market. The company's subsidiary entered into an agreement to acquire the USFDA-approved Abbreviated New Drug Application (ANDA) for Tramadol tablets from APDM Pharmaceuticals, thereby strengthening its pain management portfolio. This acquisition aligns with the company's strategy to expand its presence in the U.S. generics market, with Tramadol's market size estimated at approximately $61.95 million for 2024.
Furthermore, the company announced the acquisition of FDA-approved Enalapril Maleate Tablets from Wockhardt, a development that resulted in a 3% rise in its stock price. Senores Pharmaceuticals also acquired USFDA-approved Topiramate tablets from Wockhardt, funded through IPO proceeds, leading to a 1.53% increase in stock value upon the news.
The company operates a dedicated Critical Care Injectables Business, supplying critical care injectables to hospitals across India via a network of distributors. It also manufactures Active Pharmaceutical Ingredients (APIs) for both the domestic market and SAARC countries. In 2021, Senores Pharmaceuticals established a wholly-owned subsidiary, Senores Pharmaceuticals Inc, in the US, and diversified into the API segment through the acquisition of Ratnagene Lifescience Private Limited.
A state-of-the-art API facility has been commissioned at Mehsana. This facility is poised to enhance Senores' product offerings and bolster its competitiveness in regulated markets, particularly within the Contract Development and Manufacturing Organization (CDMO) and Contract Manufacturing Organization (CMO) businesses.
In Q4 FY25, the company demonstrated significant growth, achieving a total income of ₹410 crores, marking a 91% year-over-year increase, despite encountering operational challenges such as delays in revenue realization due to packaging line issues. Strategic initiatives are in motion to expand the ANDA portfolio, with plans to launch 31 new products in FY26. These initiatives are aimed at increasing market share and securing government contracts in the U.S. The management maintains an optimistic outlook regarding doubling profit after tax, supported by a robust product pipeline.
The company has shown operational improvements, with debtor days improving from 177 to 114 days. Despite consistently reporting profits, the company is currently not distributing dividends, choosing instead to reinvest profits back into the business for sustained growth.
Current key investment metrics include a stock P/E ratio of 47.5 and the stock trading at 3.44 times its book value of ₹171. Analysts hold a positive outlook for Senores Pharmaceuticals, with 100% of analysts recommending a 'BUY' rating. The average target price is set at ₹880, indicating a potential upside of 53.58% from current levels.
Senores Pharmaceuticals presents a compelling investment opportunity within the pharmaceutical sector, underpinned by strong financial performance and strategic market positioning in both regulated and emerging markets. The company's focus on complex generics, strategic acquisitions, and expansion into high-value therapeutic segments strategically positions it for sustained growth in the global pharmaceutical landscape.
